Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rADAMTS13 (BAX 930 / TAK-755) in congenital TTP (cTTP/USS/hTTP) prophylaxis and on-demand treatment
jRCT2080224906Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in thrombotic thrombocytopenic purpura (TTP) comparing BAX 930/TAK-755 arm with Standard-of-care arm (2 arms). Started Oct 2019; status: completed.
02
Drugs
Apadamtase alfa
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on jRCT2080224906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224906.